Research model, not device output. Trajectories are modeled from published immunopathology literature using biologically-informed priors — not Q-SENS measurements, clinical trials, or patient data. Not for clinical, diagnostic, or research use.
Interactive model

Cytokine intelligence, simulated.

The Q-SENS panel measures five cytokines from a finger-prick in under ten minutes. This model shows how those readings move across disease states, patient profiles, and time — the immune signatures the platform is built to detect.

IL-6 IL-10 TNF-α IFN-γ IL-1β PCT*
Modifying factors
Patient profile
Adjust demographics and clinical status. These modify peak amplitude, kinetics, and marker ratios using published immunological priors, and update every view below in real time.
Age35 yr
BMI24
Biological sex
Immunosuppressed
Vaccinated (bio threats)
Disease severity / activity
Inflammatory & oncologic
Select a condition
Chronic inflammatory and oncologic conditions where cytokine profiling supports diagnosis, therapy-target identification, biologic monitoring, and detection of complications.
Time 2w
Time-course immune response
Modeled trajectories from published immunopathology. Each marker is shown as fold-elevation above its upper limit of normal (ULN). Drag the time control to move the cursor.
Select a condition above.
Pattern flags at selected time point
Clinical rationale
The biological basis for the observed cytokine pattern, its diagnostic implications, and how Q-SENS supports decision-making for the selected condition.
Comparative snapshot
at 2w
Literature-derived cytokine patterns for all inflammatory and oncologic conditions at the selected time point. Click any row to select that condition above.
Condition Category IL-6 IL-10 TNF-α IFN-γ IL-1β PCT*
1× (ULN)20×50×100×200×+
Panel readout at 2w
Absolute concentrations and fold-elevation at the selected time point for the active condition and current patient profile.
The panel
Marker selection rationale
Each marker in the panel was selected for its distinct biological role, broad relevance across threat categories, and measurability at clinically meaningful concentrations from capillary blood.

Interested in Q-SENS?

We're partnering with pharma and biotech organizations for RUO research programs, and meeting investors for our seed round.

Request a conversation → The technology